Stock-Moving Catalysts Anticipated for Regeneus in Q4/16

Source: The Life Sciences Report  (09/28/2016)
Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan. read more >

Imagin, a Better Way to Detect Bladder Cancer

Contributed Opinion
Source: Bob Moriarty for The Life Sciences Report  (09/20/2016)
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. read more >

Regeneus Secures Government Funding for R&D

Source: The Life Sciences Report  (09/14/2016)
Regeneus Secures Government Funding for R&D
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. read more >

Three Shots on Goal in Q4/16 for DURECT Corp.

Source: The Life Sciences Report  (09/08/2016)
Three Shots on Goal in Q4/16 for DURECT Corp.
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. read more >

Soligenix's Diversified Pipeline Advances on All Fronts

Source: The Life Sciences Report  (08/31/2016)
Soligenix's Diversified Pipeline Advances on All Fronts
The late-stage biopharmaceutical company Soligenix has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape. read more >

Inovio Expands Ebola Vaccine Trial

Source: The Life Sciences Report  (08/24/2016)
Inovio Expands Ebola Vaccine Trial
Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination. read more >
Management Q&A: View from the Top

Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs

Managment Q&A: View from the Top
Source: The Life Sciences Report  (08/17/2016)
Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. read more >
Expert Investing Ideas

"We are initiating coverage of ATNM with a Buy rating."

–Joseph Pantginis, ROTH Capital Partners


NASDAQ Biotech ARCA Pharmaceutical

The ASX: Investing in an Emerging Biotech Frontier

Contributed Opinion
Source: Stuart Roberts for The Life Sciences Report  (08/10/2016)
The ASX: Investing in an Emerging Biotech Frontier
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. read more >

Resverlogix Seeks Orphan Status for Lead Drug Candidate

Source: The Life Sciences Report  (08/03/2016)
Resverlogix Seeks Orphan Status for Lead Drug Candidate
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications. read more >

Nobilis Moves Forward with New President and New Canaccord Coverage

Source: The Life Sciences Report  (07/20/2016)
Nobilis Moves Forward with New President and New Canaccord Coverage
Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy. read more >

DURECT's Abuse-Deterrent Opioid Poised for FDA Approval

Source: Tracy Salcedo of The Life Sciences Report  (07/13/2016)
DURECT's Abuse-Deterrent Opioid Poised for FDA Approval
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative. read more >
Biotech Watchlist 2016